NO20025146L - Isolering og karakterisering av csa-operonet (ETEC-CS4 pili) og fremgangsmåter for anvendelse derav - Google Patents
Isolering og karakterisering av csa-operonet (ETEC-CS4 pili) og fremgangsmåter for anvendelse deravInfo
- Publication number
- NO20025146L NO20025146L NO20025146A NO20025146A NO20025146L NO 20025146 L NO20025146 L NO 20025146L NO 20025146 A NO20025146 A NO 20025146A NO 20025146 A NO20025146 A NO 20025146A NO 20025146 L NO20025146 L NO 20025146L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- csa operon
- etec
- pili
- characterization
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000012512 characterization method Methods 0.000 title 1
- 238000002955 isolation Methods 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/255—Salmonella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19862600P | 2000-04-20 | 2000-04-20 | |
| PCT/US2001/012914 WO2001081582A2 (en) | 2000-04-20 | 2001-04-20 | Isolation and characterization of the csa operon (etec-cs4 pili) and methods of using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20025146D0 NO20025146D0 (no) | 2002-10-25 |
| NO20025146L true NO20025146L (no) | 2002-12-05 |
Family
ID=32849273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20025146A NO20025146L (no) | 2000-04-20 | 2002-10-25 | Isolering og karakterisering av csa-operonet (ETEC-CS4 pili) og fremgangsmåter for anvendelse derav |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6902736B2 (pl) |
| EP (1) | EP1280912B1 (pl) |
| AT (1) | ATE349531T1 (pl) |
| AU (2) | AU5554301A (pl) |
| CA (1) | CA2407523A1 (pl) |
| CZ (1) | CZ20023795A3 (pl) |
| DE (1) | DE60125528T2 (pl) |
| ES (1) | ES2276785T3 (pl) |
| HU (1) | HUP0300297A3 (pl) |
| MX (1) | MXPA02010407A (pl) |
| NO (1) | NO20025146L (pl) |
| NZ (1) | NZ522272A (pl) |
| PL (1) | PL359293A1 (pl) |
| WO (1) | WO2001081582A2 (pl) |
| ZA (1) | ZA200209042B (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1372708E (pt) * | 2001-02-13 | 2008-09-29 | Us Gov Sec Army | Vacina para imunização transcutânea |
| GB0121998D0 (en) * | 2001-09-11 | 2001-10-31 | Acambis Res Ltd | Attenuated bacteria useful in vaccines |
| WO2003045440A1 (en) * | 2001-11-28 | 2003-06-05 | Angiogenetics Sweden Ab | Regulation of hypoxia-inducible gene expression with antisense inhibitory pas domain protein |
| WO2003076643A2 (en) * | 2002-02-25 | 2003-09-18 | U.S. Army Medical Research And Materiel Command | Method of making cs6 antigen vaccine for treating, preventing, or inhibiting enterotoxigenic escherichia coli infections |
| US9328150B2 (en) | 2005-01-11 | 2016-05-03 | The United States Of America As Represented By The Secretary Of The Navy | Recombinant polypeptide construct comprising multiple enterotoxigenic Escherichia coli fimbrial subunits |
| EP1855718B1 (en) | 2005-01-11 | 2016-10-12 | The United States of America as represented by The Secretary of The Navy | Donor strand complemented adhesins as immunogen against Escherichia coli. |
| WO2007117339A2 (en) * | 2006-01-11 | 2007-10-18 | The United States Of America As Respresented By The Secretary Of The Navy | Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli |
| CA2726293C (en) * | 2008-06-03 | 2017-02-28 | University Of Maryland, Baltimore | Non-hemolytic clya for excretion of proteins |
| US9452205B2 (en) | 2012-09-24 | 2016-09-27 | Montana State University | Recombinant Lactococcus lactis expressing Escherichia coli colonization factor antigen I (CFA/I) fimbriae and their methods of use |
| US10500261B2 (en) | 2014-11-05 | 2019-12-10 | The United States Of America As Represented By The Secretary Of The Navy | Synthetic antigen constructs against campylobacter jejuni |
| JP2017537145A (ja) | 2014-11-05 | 2017-12-14 | ザ ユナイテッド ステイツ オブ アメリカ アズ レプレゼンティッド バイ ザ セクレタリー オブ ザ ネイビーＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ Ｏｆ Ａｍｅｒｉｃａ Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｓｅｃｒｅｔａｒｙ Ｏｆ Ｔｈｅ Ｎａｖｙ | カンピロバクター・ジェジュニに対する合成抗原コンストラクト |
| CN117051021B (zh) * | 2023-08-01 | 2024-09-20 | 扬州大学 | 非诱导型表达鸡白痢沙门菌Bcf菌毛的鸡伤寒沙门菌重组菌及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5417986A (en) * | 1984-03-16 | 1995-05-23 | The United States Of America As Represented By The Secretary Of The Army | Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| KR19980703876A (ko) | 1995-04-14 | 1998-12-05 | 스티븐 엘. 허스트 | 분산성이 개선된 분말화된 약학적 조성물 |
| US5914114A (en) * | 1995-06-02 | 1999-06-22 | The United States Of America As Represented By The Secretary Of The Army | Method of raising antibodies against E. coli of the family CS4-CFA/I |
| US5932715A (en) * | 1995-06-07 | 1999-08-03 | Emory University | Nucleotide sequences encoding a CS2 pilin protein |
| WO1997044446A1 (en) | 1996-05-24 | 1997-11-27 | University Of Maryland At Baltimore | Dna vaccines for eliciting a mucosal immune response |
| US6190669B1 (en) | 1998-05-13 | 2001-02-20 | University Of Maryland, Baltimore | Attenuated mutants of salmonella which constitutively express the Vi antigen |
-
2001
- 2001-04-20 PL PL01359293A patent/PL359293A1/pl not_active Application Discontinuation
- 2001-04-20 CA CA002407523A patent/CA2407523A1/en not_active Abandoned
- 2001-04-20 NZ NZ522272A patent/NZ522272A/en unknown
- 2001-04-20 WO PCT/US2001/012914 patent/WO2001081582A2/en not_active Ceased
- 2001-04-20 US US09/839,894 patent/US6902736B2/en not_active Expired - Lifetime
- 2001-04-20 MX MXPA02010407A patent/MXPA02010407A/es active IP Right Grant
- 2001-04-20 ES ES01928715T patent/ES2276785T3/es not_active Expired - Lifetime
- 2001-04-20 HU HU0300297A patent/HUP0300297A3/hu unknown
- 2001-04-20 DE DE60125528T patent/DE60125528T2/de not_active Expired - Lifetime
- 2001-04-20 AU AU5554301A patent/AU5554301A/xx active Pending
- 2001-04-20 CZ CZ20023795A patent/CZ20023795A3/cs unknown
- 2001-04-20 AT AT01928715T patent/ATE349531T1/de not_active IP Right Cessation
- 2001-04-20 AU AU2001255543A patent/AU2001255543B2/en not_active Ceased
- 2001-04-20 EP EP01928715A patent/EP1280912B1/en not_active Expired - Lifetime
-
2002
- 2002-10-25 NO NO20025146A patent/NO20025146L/no not_active Application Discontinuation
- 2002-11-07 ZA ZA200209042A patent/ZA200209042B/en unknown
-
2005
- 2005-02-10 US US11/053,876 patent/US7399474B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE60125528D1 (de) | 2007-02-08 |
| MXPA02010407A (es) | 2003-05-23 |
| NO20025146D0 (no) | 2002-10-25 |
| AU2001255543B2 (en) | 2005-06-23 |
| PL359293A1 (pl) | 2004-08-23 |
| EP1280912B1 (en) | 2006-12-27 |
| EP1280912A2 (en) | 2003-02-05 |
| WO2001081582A3 (en) | 2002-05-02 |
| WO2001081582A2 (en) | 2001-11-01 |
| US6902736B2 (en) | 2005-06-07 |
| US20050136070A1 (en) | 2005-06-23 |
| AU5554301A (en) | 2001-11-07 |
| ZA200209042B (en) | 2004-03-08 |
| HUP0300297A3 (en) | 2005-09-28 |
| CA2407523A1 (en) | 2001-11-01 |
| HUP0300297A2 (en) | 2003-05-28 |
| NZ522272A (en) | 2004-09-24 |
| ES2276785T3 (es) | 2007-07-01 |
| CZ20023795A3 (cs) | 2003-04-16 |
| US7399474B2 (en) | 2008-07-15 |
| ATE349531T1 (de) | 2007-01-15 |
| US20020176868A1 (en) | 2002-11-28 |
| DE60125528T2 (de) | 2007-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1373296T3 (da) | Proteiner, der frembringer et ændret immunogent respons, og fremgangsmåder til fremstilling og anvendelse deraf | |
| CY1118443T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
| NO20003958L (no) | Tumor assosierte antigen derivater fra MAGE familien, og nuklein syre sekvenser som koder for disse, anvendt for fremstilling av fusjons proteiner og for vaksinesammensetninger | |
| DK1129190T3 (da) | Human TSLP DNA og polypeptider | |
| WO2003057713A3 (en) | Proteases producing an altered immunogenic response and methods of making and using the same | |
| NO331103B1 (no) | Polypeptid for induksjon av immunrespons mot Streptococcus Pneumoniae, polynukleotid og ekspresjonsvektor inneholdende dette samt vertscelle og fremgangsmate for produksjon av polypeptidet og vaksinesammensetning omfattende dette | |
| WO2004043407A3 (en) | Methods and products for treating staphylococcal infections | |
| NO20025146D0 (no) | Isolering og karakterisering av CSA-operon (ETEC-CS4 PILI) og fremgangsmÕter for Õ anvende det samme | |
| YU9403A (sh) | Anti-dualna antitela integrina, kompozicije, postupci i primene | |
| DK1589031T3 (da) | Fremstillingaf polyketider og andre naturlige produkter | |
| WO2002097048A3 (en) | ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES | |
| WO2005056600A3 (en) | Monoclonal antibodies that bind or neutralize dengue virus | |
| MXPA02006888A (es) | Flavivirus recombinantes y metodos para utilizar los mismos. | |
| SI1675956T1 (sl) | Minimalno zaporedje dna, ki deluje kot izolirni element kromatina in njegova uporaba pri ekspresiji proteinov | |
| FR21C1005I2 (fr) | Antigenes de streptococcus pyogenes et fragments d'adn correspondants | |
| DK1165759T3 (da) | Polypeptider, der har forgrenende enzymaktivitet, og nukleinsyrer, der koder for samme | |
| MXPA05005202A (es) | Vacuna. | |
| TW200508246A (en) | Anti-dengue virus antibodies, compositions, methods and uses | |
| DE69836520D1 (de) | Clostridium perfringens Impfstoff | |
| PT1290160E (pt) | Polipeptideos pellino humanos | |
| AU2002310474A1 (en) | Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same | |
| SG146662A1 (en) | Method | |
| WO2007050095A3 (en) | Improved vaccines and methods for using the same | |
| NO20011537L (no) | Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes | |
| DE69734828D1 (de) | 5-aminolevulinsaure synthase aus aspergillus oryzae und dafuer kodierende nukleinsaeure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE | Reestablishment of rights (par. 72 patents act) | ||
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |